I believe that B2B is where we should aim. The technology is good but it is useless qithout a good salesman.
- Forums
- ASX - By Stock
- CDE
- Ann: Critical patent granted by USPTO enhancing value of MM asset
Ann: Critical patent granted by USPTO enhancing value of MM asset, page-16
Featured News
Add CDE (ASX) to my watchlist
(20min delay)
|
|||||
Last
0.2¢ |
Change
0.001(100%) |
Mkt cap ! $3.961M |
Open | High | Low | Value | Volume |
0.1¢ | 0.2¢ | 0.1¢ | $10.75K | 6.750M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
19 | 27140390 | 0.1¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
0.2¢ | 33596219 | 26 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
18 | 26639390 | 0.001 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
0 | 0 | 0.000 |
Price($) | Vol. | No. |
---|---|---|
0.002 | 34596219 | 28 |
0.003 | 6751776 | 9 |
0.004 | 9304781 | 7 |
0.005 | 2715000 | 6 |
0.006 | 55000 | 1 |
Last trade - 14.57pm 13/11/2024 (20 minute delay) ? |
Featured News
CDE (ASX) Chart |
The Watchlist
NUZ
NEURIZON THERAPEUTICS LIMITED
Michael Thurn, CEO & MD
Michael Thurn
CEO & MD
SPONSORED BY The Market Online